ketanserin has been researched along with Systemic Inflammatory Response Syndrome in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Systemic Inflammatory Response Syndrome: A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kats, S | 1 |
| Schönberger, JP | 1 |
| Brands, R | 1 |
| Seinen, W | 1 |
| van Oeveren, W | 1 |
1 review available for ketanserin and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update.
Topics: Adrenal Cortex Hormones; Alkaline Phosphatase; Anti-Infective Agents; Antibodies; Cardiopulmonary By | 2011 |